Who Paid My Doc
Bryan Borland
Addiction Medicine Columbus, OH Doctor of Osteopathy
NPI 1457643637 CMS profile 5703868
815 W Broad St Ste 200, Columbus, OH 43222
General payments
$397
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Bryan Borland of Columbus, OH is reported in the CMS Open Payments database as having received $397 across 16 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 59th percentile of Addiction Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
6 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $16 | 1 | |
| 2023 | General | $16 | 1 | |
| 2022 | General | $92 | 5 | |
| 2021 | General | $31 | 2 | |
| 2020 | General | $82 | 4 | |
| 2019 | General | $160 | 3 |
Beside peers
- Bryan Borland
- Addiction Medicine median
- Middle half of Addiction Medicine
- National median
In program year 2025, general payments to Bryan Borland were reported at $16. Among 146 Addiction Medicine profiles paid that year, the median was $140 and the middle half received between $52 and $540.
Show as a table
| Year | Bryan Borland | Addiction Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $160 | $120 | $36–$323 | $163 |
| 2020 | $82 | $87 | $33–$262 | $114 |
| 2021 | $31 | $94 | $31–$394 | $132 |
| 2022 | $92 | $125 | $45–$667 | $149 |
| 2023 | $16 | $143 | $44–$445 | $160 |
| 2024 | $0 | $122 | $40–$490 | $164 |
| 2025 | $16 | $140 | $52–$540 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 8 drugsPart D claims
168
Drug cost
$3,858
Branded share of claims
37.5%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl | Brand | 43 | $2,709 | |
| Olanzapine | Generic | 20 | $440 | |
| Bupropion Xl Bupropion Hcl | Brand | 20 | $228 | |
| Prazosin Hcl | Generic | 15 | $218 | |
| Quetiapine Fumarate | Generic | 11 | $104 | |
| Fluoxetine Hcl | Generic | 33 | $86 | |
| Trazodone Hcl | Generic | 13 | $39 | |
| Sertraline Hcl | Generic | 13 | $34 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 382 Part D prescribers listed as Addiction Medicine; they describe a distribution and say nothing about conduct.
Records
16 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Addiction Medicine in Ohio
Related records
Addiction Medicine in Ohio
Practitioners in the same specialty and state, ranked by reported value.
All Addiction Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Ohio
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.